GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlycoNex Inc (ROCO:4168) » Definitions » Cyclically Adjusted PB Ratio

GlycoNex (ROCO:4168) Cyclically Adjusted PB Ratio : 1.09 (As of Jun. 18, 2024)


View and export this data going back to 2012. Start your Free Trial

What is GlycoNex Cyclically Adjusted PB Ratio?

As of today (2024-06-18), GlycoNex's current share price is NT$27.00. GlycoNex's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was NT$24.84. GlycoNex's Cyclically Adjusted PB Ratio for today is 1.09.

The historical rank and industry rank for GlycoNex's Cyclically Adjusted PB Ratio or its related term are showing as below:

ROCO:4168' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.97   Med: 1.15   Max: 1.72
Current: 1.07

During the past years, GlycoNex's highest Cyclically Adjusted PB Ratio was 1.72. The lowest was 0.97. And the median was 1.15.

ROCO:4168's Cyclically Adjusted PB Ratio is ranked better than
61.04% of 657 companies
in the Biotechnology industry
Industry Median: 1.67 vs ROCO:4168: 1.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

GlycoNex's adjusted book value per share data for the three months ended in Mar. 2024 was NT$11.113. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is NT$24.84 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


GlycoNex Cyclically Adjusted PB Ratio Historical Data

The historical data trend for GlycoNex's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlycoNex Cyclically Adjusted PB Ratio Chart

GlycoNex Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.26 1.20 1.18 1.19

GlycoNex Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.19 1.21 1.07 1.19 1.00

Competitive Comparison of GlycoNex's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, GlycoNex's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GlycoNex's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlycoNex's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where GlycoNex's Cyclically Adjusted PB Ratio falls into.



GlycoNex Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

GlycoNex's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=27.00/24.84
=1.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, GlycoNex's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=11.113/131.7762*131.7762
=11.113

Current CPI (Mar. 2024) = 131.7762.

GlycoNex Quarterly Data

Book Value per Share CPI Adj_Book
201406 29.701 100.560 38.921
201409 29.381 100.428 38.552
201412 29.093 99.070 38.698
201503 28.675 99.621 37.931
201506 28.437 100.684 37.219
201509 28.048 100.392 36.816
201512 27.756 99.792 36.652
201603 26.883 100.470 35.260
201606 26.442 101.688 34.266
201609 26.131 101.861 33.805
201612 25.631 101.863 33.158
201703 25.781 102.862 33.028
201706 25.266 103.349 32.216
201709 24.780 104.136 31.357
201712 24.210 104.011 30.673
201803 23.341 105.290 29.213
201806 22.053 106.317 27.334
201809 21.407 106.507 26.486
201812 20.100 105.998 24.988
201903 19.434 107.251 23.878
201906 18.379 108.070 22.411
201909 17.439 108.329 21.213
201912 17.034 108.420 20.704
202003 16.471 108.902 19.931
202006 18.340 108.767 22.220
202009 16.521 109.815 19.825
202012 15.765 109.897 18.904
202103 15.309 111.754 18.052
202106 14.827 114.631 17.045
202109 14.382 115.734 16.375
202112 13.914 117.630 15.587
202203 13.588 121.301 14.761
202206 13.458 125.017 14.186
202209 14.538 125.227 15.298
202212 13.498 125.222 14.205
202303 12.965 127.348 13.416
202306 12.954 128.729 13.261
202309 12.390 129.860 12.573
202312 11.796 129.419 12.011
202403 11.113 131.776 11.113

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GlycoNex  (ROCO:4168) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


GlycoNex Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of GlycoNex's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GlycoNex (ROCO:4168) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.

GlycoNex (ROCO:4168) Headlines

No Headlines